Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
Summary: Mucosal COVID-19 vaccines are needed to block SARS-CoV-2 infection at the mucosal site. Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD) mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those induced by the intramuscu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004223021107 |
| _version_ | 1797647822663712768 |
|---|---|
| author | Xiaoqing Guan Abhishek K. Verma Gang Wang Juan Shi Stanley Perlman Lanying Du |
| author_facet | Xiaoqing Guan Abhishek K. Verma Gang Wang Juan Shi Stanley Perlman Lanying Du |
| author_sort | Xiaoqing Guan |
| collection | DOAJ |
| description | Summary: Mucosal COVID-19 vaccines are needed to block SARS-CoV-2 infection at the mucosal site. Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD) mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those induced by the intramuscular injection of the same vaccine or Omicron-S subunit vaccine, as well as high mucosal IgA antibody responses. It elicited broadly neutralizing antibodies against the original SARS-CoV-2 strain, Delta and Omicron BA1/BA2 variants, completely protecting transgenic mice from lethal challenge with a Delta variant, including complete absence of weight loss. Of note, intramuscular priming with the Omicron-S protein followed by intranasal boosting with the Delta-RBD protein improved the vaccine’s ability to generate broad-spectrum neutralizing antibodies against recent BA5 and XBB Omicron variants. Overall, this vaccine has the potential to prevent the SARS-CoV-2 infection of the respiratory mucosa, while the i.m. priming and i.n. boosting vaccination strategy may offer protection against known and emerging SARS-CoV-2 variants. |
| first_indexed | 2024-03-11T15:22:04Z |
| format | Article |
| id | doaj.art-6affcc00b8e043c3973eca6624065293 |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-03-11T15:22:04Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-6affcc00b8e043c3973eca66240652932023-10-28T05:09:21ZengElsevieriScience2589-00422023-10-012610108033Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challengeXiaoqing Guan0Abhishek K. Verma1Gang Wang2Juan Shi3Stanley Perlman4Lanying Du5Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USADepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USAInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USAInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USADepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA; Department of Pediatrics, University of Iowa, Iowa City, IA, USA; Corresponding authorInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA; Corresponding authorSummary: Mucosal COVID-19 vaccines are needed to block SARS-CoV-2 infection at the mucosal site. Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD) mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those induced by the intramuscular injection of the same vaccine or Omicron-S subunit vaccine, as well as high mucosal IgA antibody responses. It elicited broadly neutralizing antibodies against the original SARS-CoV-2 strain, Delta and Omicron BA1/BA2 variants, completely protecting transgenic mice from lethal challenge with a Delta variant, including complete absence of weight loss. Of note, intramuscular priming with the Omicron-S protein followed by intranasal boosting with the Delta-RBD protein improved the vaccine’s ability to generate broad-spectrum neutralizing antibodies against recent BA5 and XBB Omicron variants. Overall, this vaccine has the potential to prevent the SARS-CoV-2 infection of the respiratory mucosa, while the i.m. priming and i.n. boosting vaccination strategy may offer protection against known and emerging SARS-CoV-2 variants.http://www.sciencedirect.com/science/article/pii/S2589004223021107ImmunologyVirology |
| spellingShingle | Xiaoqing Guan Abhishek K. Verma Gang Wang Juan Shi Stanley Perlman Lanying Du Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge iScience Immunology Virology |
| title | Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge |
| title_full | Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge |
| title_fullStr | Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge |
| title_full_unstemmed | Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge |
| title_short | Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge |
| title_sort | glycosylated delta receptor binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against sars cov 2 challenge |
| topic | Immunology Virology |
| url | http://www.sciencedirect.com/science/article/pii/S2589004223021107 |
| work_keys_str_mv | AT xiaoqingguan glycosylateddeltareceptorbindingdomainmucosalvaccineelicitsbroadlyneutralizingantibodieswithprotectionagainstsarscov2challenge AT abhishekkverma glycosylateddeltareceptorbindingdomainmucosalvaccineelicitsbroadlyneutralizingantibodieswithprotectionagainstsarscov2challenge AT gangwang glycosylateddeltareceptorbindingdomainmucosalvaccineelicitsbroadlyneutralizingantibodieswithprotectionagainstsarscov2challenge AT juanshi glycosylateddeltareceptorbindingdomainmucosalvaccineelicitsbroadlyneutralizingantibodieswithprotectionagainstsarscov2challenge AT stanleyperlman glycosylateddeltareceptorbindingdomainmucosalvaccineelicitsbroadlyneutralizingantibodieswithprotectionagainstsarscov2challenge AT lanyingdu glycosylateddeltareceptorbindingdomainmucosalvaccineelicitsbroadlyneutralizingantibodieswithprotectionagainstsarscov2challenge |